Table 4 Multivariable analyses in the... | American Society of Hematology

Table 4

Multivariable analyses in the training cohort

Variable	OS		PFS		Relapse		NRM
Variable	HR	P	HR	P	HR	P	HR	P
Risk group (DRI)
Low	0.6	< .0001	0.6	< .0001	0.4	< .0001	1.0	0.9
Intermediate	Ref		Ref		Ref		Ref
High	1.8	< .0001	1.9	< .0001	2.0	< .0001	1.1	.6
Very high	3.1	< .0001	3.2	< .0001	2.5	.0002	1.2	.5
Age, y
< 40	0.7	< .0001	0.7	.0005	1.1	.7	0.6	< .0001
40-54	Ref		Ref		Ref		Ref
55-64	1.1	.4	1.0	.6	0.9	.6	1.2	.2
≥ 65	1.2	.10	1.0	.7	1.1	.3	0.7	.12
HSCT on protocol
No	Ref		Ref		Ref		Ref
Yes	0.7	< .0001	0.7	< .0001	0.8	.009	1.1	.6
Donor
MRD	0.8	.03	1.0	.8	1.5	< .0001	0.5	< .0001
MUD	Ref	.0007	Ref	.004	Ref	.9	Ref	.004
Mismatched	1.5		1.4		1.0		1.6
Graft source
BM	Ref		Ref		Ref		Ref
PB	N/A^a		N/A^a		0.8	.09	1.0	.8
UCB	1.5	.13	1.4	.17	0.7	.11	1.9	.017
Conditioning	N/A^a		N/A^a
MAC					Ref		Ref
RIC					3.0	< .0001	0.3	< .0001
GVHD prophylaxis
CnI/Mtx	Ref		Ref		Ref		Ref
CnI/Siro ± Mtx	1.0	.9	1.1	.5	1.2	.08	0.7	.007
CnI/MMF	0.9	.6	0.8	.3	0.9	.6	1.0	1.0
TCD	1.6	.04	1.5	.08	1.3	.5	1.4	.3
Other	2.0	.005	1.6	.04	1.0	.9	1.8	.08
CMV serostatus
Donor and patient −	Ref		Ref		Ref		Ref
Donor or patient +	1.1	.4	1.0	1.0	0.9	.5	1.1	.4
Patient sex
Male	Ref		Ref		Ref		Ref
Female	0.9	.03	0.9	.2	1.1	.3	0.8	.018
Therapy-related disease
No	Ref		Ref		Ref		Ref
Yes	1.0	.9	0.9	.3	0.8	.16	1.0	.9
Transformed disease
No	Ref		Ref		Ref		Ref
Yes	1.1	.3	1.2	.13	1.2	.3	1.1	.7
Year of HSCT*	N/A*		N/A*		N/A*		N/A*

Variable	OS		PFS		Relapse		NRM
Variable	HR	P	HR	P	HR	P	HR	P
Risk group (DRI)
Low	0.6	< .0001	0.6	< .0001	0.4	< .0001	1.0	0.9
Intermediate	Ref		Ref		Ref		Ref
High	1.8	< .0001	1.9	< .0001	2.0	< .0001	1.1	.6
Very high	3.1	< .0001	3.2	< .0001	2.5	.0002	1.2	.5
Age, y
< 40	0.7	< .0001	0.7	.0005	1.1	.7	0.6	< .0001
40-54	Ref		Ref		Ref		Ref
55-64	1.1	.4	1.0	.6	0.9	.6	1.2	.2
≥ 65	1.2	.10	1.0	.7	1.1	.3	0.7	.12
HSCT on protocol
No	Ref		Ref		Ref		Ref
Yes	0.7	< .0001	0.7	< .0001	0.8	.009	1.1	.6
Donor
MRD	0.8	.03	1.0	.8	1.5	< .0001	0.5	< .0001
MUD	Ref	.0007	Ref	.004	Ref	.9	Ref	.004
Mismatched	1.5		1.4		1.0		1.6
Graft source
BM	Ref		Ref		Ref		Ref
PB	N/A^a		N/A^a		0.8	.09	1.0	.8
UCB	1.5	.13	1.4	.17	0.7	.11	1.9	.017
Conditioning	N/A^a		N/A^a
MAC					Ref		Ref
RIC					3.0	< .0001	0.3	< .0001
GVHD prophylaxis
CnI/Mtx	Ref		Ref		Ref		Ref
CnI/Siro ± Mtx	1.0	.9	1.1	.5	1.2	.08	0.7	.007
CnI/MMF	0.9	.6	0.8	.3	0.9	.6	1.0	1.0
TCD	1.6	.04	1.5	.08	1.3	.5	1.4	.3
Other	2.0	.005	1.6	.04	1.0	.9	1.8	.08
CMV serostatus
Donor and patient −	Ref		Ref		Ref		Ref
Donor or patient +	1.1	.4	1.0	1.0	0.9	.5	1.1	.4
Patient sex
Male	Ref		Ref		Ref		Ref
Female	0.9	.03	0.9	.2	1.1	.3	0.8	.018
Therapy-related disease
No	Ref		Ref		Ref		Ref
Yes	1.0	.9	0.9	.3	0.8	.16	1.0	.9
Transformed disease
No	Ref		Ref		Ref		Ref
Yes	1.1	.3	1.2	.13	1.2	.3	1.1	.7
Year of HSCT*	N/A*		N/A*		N/A*		N/A*

CnI indicates calcineurin inhibitor; DRI, disease risk index (see text); HR, hazard ratio; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; N/A, not applicable; OS, overall survival; PB, peripheral blood; PFS, progression-free survival; RIC, reduced-intensity conditioning; Siro, sirolimus; TCD, T-cell depletion; and UCB, umbilical cord blood.

OS and PFS models are stratified on conditioning intensity, graft source (BM vs PB), and year of transplantation (2000-2001, 2002-2004, 2005-2009), so no HRs or P values are provided for those variables.

View Large

This Feature Is Available To Subscribers Only